Defibrillators Market Global Report 2026

The defibrillators market size has grown strongly in recent years. It will grow from $10.99 billion in 2025 to $11.81 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period was driven by increasing prevalence of cardiovascular diseases, rising demand for emergency cardiac care equipment, growing adoption of automated external defibrillators, increasing healthcare infrastructure development, and rising awareness about sudden cardiac arrest management.

The defibrillators market size is expected to see strong growth in the next few years. It will grow to $15.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth during the forecast period is attributed to increasing adoption of connected defibrillator technologies, growing demand for home-based cardiac care solutions, rising integration of AI-based cardiac monitoring, increasing healthcare digitization initiatives, and growing focus on advanced portable cardiac devices. Major trends in the forecast period include increasing development of advanced cardiac rhythm monitoring technologies, growing adoption of portable and wearable defibrillation devices, rising integration of real-time patient monitoring capabilities, increasing focus on improved defibrillator battery efficiency and performance, and growing demand for automated emergency cardiac care solutions.

The rising incidence of cardiovascular diseases is expected to drive the growth of the defibrillators market in the coming years. Cardiovascular diseases are disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, arrhythmias, and stroke, and they continue to be one of the leading causes of death worldwide. The increasing incidence of cardiovascular diseases is primarily attributed to population aging, which has resulted in a larger number of individuals being at risk of heart disease and stroke. Defibrillators play a critical role in the treatment of cardiovascular diseases by providing rapid intervention for sudden cardiac arrest and severe cardiac rhythm disorders, thereby improving survival rates and reducing cardiovascular-related mortality. For instance, in August 2025, according to a report published by the National Center for Biotechnology Information (NCBI), a division of the US-based National Library of Medicine (NLM), the prevalence of cardiovascular disease is projected to increase by 90.0% between 2025 and 2050, with crude mortality expected to rise by 73.4% and crude disability-adjusted life years (DALYs) by 54.7%, while total deaths are forecast to increase from 20.5 million in 2025 to 35.6 million by 2050. Therefore, the rising incidence of cardiovascular diseases is driving the growth of the defibrillators market.

Major companies operating in the defibrillators market are concentrating on developing advanced products, such as extravascular implantable cardioverter defibrillator (EV-ICD) systems, to enhance arrhythmia management, minimize procedure-related complications, and improve patient quality of life. Extravascular implantable cardioverter defibrillator systems are advanced cardiac rhythm management devices that provide life-saving defibrillation and pacing therapies without positioning leads inside the heart or blood vessels, thereby reducing the risks associated with transvenous lead implantation. For instance, in March 2025, Medtronic plc, an Ireland-based medical technology company, launched the Aurora EV-ICD MRI device and Epsila EV MRI Lead in Japan for the treatment of life-threatening ventricular arrhythmias. The system incorporates an innovative lead placement beneath the sternum, allowing extravascular implantation while delivering antitachycardia pacing (ATP), temporary backup pacing for bradycardia, and up to 40 joules of defibrillation energy. It also provides MRI compatibility, an estimated battery life of 11.7 years, and proprietary sensing algorithms designed to minimize inappropriate shocks. This innovation highlights the increasing focus on less invasive defibrillation technologies that integrate advanced therapeutic capabilities with enhanced patient safety and improved long-term clinical outcomes.

In April 2023, Nordic Capital, a Sweden-based private equity investment firm, acquired a majority stake in Corpuls GmbH for an undisclosed amount. Through this acquisition, Nordic Capital sought to support Corpuls GmbH's global expansion, accelerate innovation in emergency medical technology, and strengthen its position in the external defibrillator and patient monitoring industry. Corpuls GmbH is a Germany-based medical technology company specializing in the development and supply of portable defibrillators.

Major companies operating in the defibrillators market are Abbott Laboratories, Medtronic plc, Stryker Corporation, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Boston Scientific Corporation, ZOLL Medical Corporation, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Biotronik SE & Co. KG, Nihon Kohden Corporation, MicroPort Scientific Corporation, Schiller AG, EDAN Instruments Inc., Comen Medical Instruments Co. Ltd., Biolight Meditech Co. Ltd., Shenzhen Biocare Bio-Medical Equipment Co. Ltd., Bexen Cardio S.L., AMI Italia S.p.A., Yuwell Medical Co. Ltd.

North America was the dominating region in the defibrillators market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the defibrillators market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the defibrillators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.